title: Multidisciplinary management of resectable rectal cancer. New developments and controversies.
abstract: Until 2004, initial surgery and, in cases of pT3 and/or node-positive disease, postoperative chemoradiotherapy (radiation plus concurrent chemotherapy) was the conventional approach for patients with clinical T3 and/or node-positive rectal cancer. The German CAO/ARO/AIO 94 trial confirmed that, compared with preoperative chemoradiotherapy, postoperative chemoradiotherapy is associated with significantly higher local failure and toxicity rates as well as a decrease in the incidence of sphincter preservation. These data resulted in a change from postoperative to preoperative chemoradiotherapy. This shift to preoperative therapy has prompted a series of new questions regarding the multidisciplinary management of rectal cancer, including: What is the ideal neoadjuvant approach (short-course vs. combined-modality therapy)? Is postoperative adjuvant chemotherapy necessary for all patients following preoperative chemoradiotherapy? Do patients with node-negative rectal cancer require pelvic radiation? What is the ideal combined-modality regimen? Does an increase in response rate translate into improved local control and survival? And lastly, what is the benefit of novel radiation sensitization and delivery techniques? This review will address these and other questions surrounding the multidisciplinary management of rectal cancer.
authors.affiliation: University of Chicago Medical Center, Chicago, Illinois, USA. bruce.minsky@uchospitals.edu
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Minsky
authors.forename: Jose G
authors.initials: JG
authors.lastname: Guillem
mesh_terms: D001003:Anal Canal; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D019583:Dose Fractionation, Radiation; D006801:Humans; D033183:Interdisciplinary Communication; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D010348:Patient Care Team; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction
chemical_list: D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents